| 书目名称 | Resistance to Targeted Therapies in Lymphomas |
| 编辑 | Ana C. Xavier,Mitchell S. Cairo |
| 视频video | |
| 概述 | Reviews different classes of target drugs that have been developed, approved, or are under investigation in the field of lymphoma therapy.Provides an overview of lymphoma biology in patients who relap |
| 丛书名称 | Resistance to Targeted Anti-Cancer Therapeutics |
| 图书封面 |  |
| 描述 | .Over the past few decades, lymphoma patient outcomes have improved as a result of multidrug chemotherapy and radiation therapy, intensification of treatment, improvement in supportive care, and better imaging and staging systems. Even more recently, there has been tremendous progress in the understanding of cancer cell biology and its microenvironment which has resulted in the development of biologic agents, also called "target" therapies. These therapies are more specific in targeting cancer cells either directly or via enhancement of the immune system. Many clinical studies have focused on biological agents in combination with traditional chemotherapy with the goal of improved outcomes, or reduced acute long term complications that are associated with lymphoma therapy. .This volume will review different classes of "target" drugs that have been developed, approved, or are under investigation in the field of lymphoma therapy. The discussion will not only be on the understanding of the mechanisms of action or clinical response of those agents, but will also help the reader to understand the nature of lymphoma biology in patients who relapse or are refractor after exposure to those |
| 出版日期 | Book 2019 |
| 关键词 | lymphoma; hodgkin lymphoma; B-cell lymphomas; T-cell lymphomas; indolent lymphomas |
| 版次 | 1 |
| doi | https://doi.org/10.1007/978-3-030-24424-8 |
| isbn_softcover | 978-3-030-24426-2 |
| isbn_ebook | 978-3-030-24424-8Series ISSN 2196-5501 Series E-ISSN 2196-551X |
| issn_series | 2196-5501 |
| copyright | Springer Nature Switzerland AG 2019 |
发表于 2025-3-21 19:44:02
